New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
In the past month, Tonix Pharmaceuticals Holding Corp. has unveiled three separate partnerships to advance its efforts towards a vaccine for novel coronavirus, including a collaboration focused on precision medicine in both preventing and treating COVID-19.
On 16 July, the biotech announced that it will work with researchers at Columbia University to investigate the immune response in healthy volunteers who either recovered from the virus or are/were asymptomatic
GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.
ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.
Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
Shares are hit as German conglomerate lowers revenue forecast.
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.
